Breyanzi Approved in Japan; but What's the Price?
Here is a brief preview of this blast: On Monday, March 22, Japan's Ministry of Health Labour and Welfare (MHLW) approved Breyanzi (CD19 CAR-T) for the treatment of diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL), transformed low-grade NHL, and high-grade B-cell lymphoma (press release). Below, Celltelligence provides insights on Breyanzi’s market access in Japan, while commenting on Breyanzi’s potential pricing and manufacturing strategies compared to key competitors Kymriah (Novartis) and Yescarta (Gilead).